43 results about "Gastric Diseases" patented technology

A lamb stomach extract Vitamin B12 preparation composition composed of lamb stomach extract and Vitamin B12 is provided. The lamb stomach extract has a chymosin activity of >40 U / g and a pepsin activity of >15 U / g, and the weight ratio of the lamb stomach extract and Vitamin B12 is 100000:0.5-5, which is useful in the treatment of moderate-to-severe chronic atrophic gastritis, intestinal metaplasia reversal, and gastric cancer prevention. Lamb stomach extract and Vitamin B12 produced synergistic or synergistic effects in specific ratios.

The invention relates to the use of herbal preparation, characterized by presence of 4 dominant compounds (carvacrol a from about 35% to about 50%, γ-terpinene from about 10% to about 30%, thymol from about 10% to about 25%, p-cymene from about 8% to about 20%, as expressed in % of total peak area in GC / MS chromatogram), obtained by mixing at least two essential oils from species selected from the group of genera Satureja L., Origanum L. and Thymus L., to prepare food supplement or medicament for treatment and prevention of gastric Helicobacter pylori infection in humans. The mixture may be placed on liquid or solid carrier and capsulated in non gastro-resistant capsules. The invention also relates to dosage regiment of herbal preparation for treatment and prevention of patients with Helicobacter pylori infection which leads to successful eradication of bacteria without any side-effects.

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The application discloses a kind of biological hybrid micro machine population oral delivery system of imitating Helicobacter pylori survival mechanism, belong to oral stomach medicine delivery technical field.The system is by active power module (flagellum driven chlamydomonas reinhardtii), environmental regulation module (acid urease modified on algal surface) and multifunctional load module (macrophage membrane wrapped drug-loaded nanoparticles) synergistic assembly through polydopamine (PDA) spatial conformation control layer is formed.Active power module utilizes self-movement ability to penetrate mucus barrier and extend intracavity retention time to 12 hours or more;Environmental regulation module produces local alkalization effect by catalyzing urea hydrolysis, provides chemical shield for system in extremely acid environment of pH 1.0-3.0, protects active power module from gastric acid inactivation;Multifunctional load module is accurately delivered to gastric epithelial cells by inflammation targeting effect, such as CRISPR / Cas9 biological macromolecule, and realizes up to 31.8% in-vivo gene editing efficiency.The application provides a non-invasive, modular active delivery platform for the precise treatment of gastric diseases such as gastritis through the synergistic effect of physical penetration, metabolic reprogramming and gene intervention.

The invention discloses an application of food-grade sodium carbonate in preparation of a medicine for regulating the acid-base balance of human tissues. The food-grade sodium carbonate conforming to the national food safety standard (GB1886.1) is used as a unique effective component and is dissolved in water to prepare sodium carbonate aqueous solutions with different concentrations, and acid metabolites accumulated in human tissues in local and whole body levels and in human tissues are treated by multiple administration routes such as external use and oral administration. The normal acid-base microenvironment of the tissue is recovered. Wherein the mass concentration of the external preparation is 0.05%-10%, and the mass concentration of the oral preparation is 0.1%-1.5%. The traditional Chinese medicine composition can be used for preventing and / or treating cancers and malignant tumors, stomach diseases related to hyperacidity, femoral head necrosis, muscle strain, frostbite and various diseases taking acid-base imbalance as a common pathological basis. The raw materials are wide in source, low in price and high in safety, the preparation process is simple, the administration scheme is systematic and complete, a single or combined administration route can be flexibly selected according to the specific condition of a patient, and individualized treatment is achieved.

A method for the industrial production of teprenone and its application. The present invention belongs to the field of teprenone synthesis. The purpose of the present invention is to solve the technical problems of the existing teprenone synthesis method, which has a long route, many side reactions, and requires the use of special reagents. The method of the present invention comprises the following steps: first, farnesene is reacted with acetoacetate in the presence of a catalyst to obtain farnesene ketone ester, which is then decarboxylated to produce farnesene acetone, and then subjected to a reduction reaction, a halogenation reaction, and a Wittig reaction to obtain teprenone. The method avoids the shortcomings of existing processes, has fewer conversion steps in the synthesis route, and produces teprenone with high yield and purity, making it suitable for industrial production. The teprenone of the present invention is used as a drug for treating gastric diseases.

The disclosure generally relates to soft gelatin oral dosage form. In particular the disclosure relates to an oral dosage form comprising a soft gelatin capsule and a liquid fill, where the liquid fill is a suspension of an H2 receptor antagonist in a hydrophobic / lipophilic excipient. The disclosure also relates to a method of treating a gastric disease or disorder by using said oral dosage form.

A pharmaceutical composition for treating helicobacter pylori infectious stomach disease belongs to the technical field of medicine, and comprises the following raw materials by weight: 5-30 g of adenophora stricta, 10-30 g of hairyvein agrimony, 10-30 g of fried coix seed, 5-20 g of lily, 10-20 g of oldenlandia diffusa, 5-30 g of pericarpium citri reticulatae, 5-20 g of bighead atractylodes rhizome, 5-30 g of dandelion, 10-30 g of sculellaria barbata, and 5-30 g of scutellaria baicalensis. By soothing liver and regulating qi, clearing heat and harmonizing stomach, strengthening spleen and calming middle-jiao and taking both symptoms and root causes into consideration, the medicine makes up the deficiency of western medicines, and pays attention to enhancing the defense function of the body, protecting the gastric mucosal barrier and correcting the gastrointestinal tract function while eliminating helicobacter pylori infection, thereby achieving the purposes of strengthening body resistance and expelling evil. The spleen-tonifying and detoxifying decoction is combined with western medicines to remarkably improve the eradication rate of helicobacter pylori, improve symptoms and relieve the side effects of the western medicines, and has the advantages of quick response, high effective rate, definite curative effect, short treatment course, no toxic or side effect, low price and the like.

The present invention relates to urine metabolite markers for gastric cancer detection and their applications. Based on the metabolomics method, the present invention detects and analyzes the metabolites of urine samples of gastric cancer patients, patients with non-cancerous gastric diseases and healthy controls, and screens 12 metabolite markers with high correlation with the development of gastric diseases. Multivariate multi-classification ROC curve analysis shows that the AUC value reaches 0.842, and the 12 differential metabolite markers have good diagnostic efficacy in distinguishing health, non-cancerous gastric diseases and gastric cancer. Further selecting 8 or 4 combinations from the 12 markers also has the same good diagnostic effect. And the above combination is further confirmed in the validation group. The metabolite combination provided by the present invention can accurately judge whether it is healthy, whether it has non-cancerous gastric diseases, and whether it has gastric cancer, which will help in the early prevention, treatment and prognosis of gastric cancer, etc., with good treatment effect and reduced treatment cost.

The invention discloses a rabeprazole pharmaceutical composition as well as a preparation method and application thereof. The invention provides a rabeprazole pharmaceutical composition, the rabeprazole pharmaceutical composition comprises an active pharmaceutical ingredient and an antacid, and the active pharmaceutical ingredient is selected from one or more of rabeprazole, rabeprazole sodium, other pharmaceutically acceptable salt forms, solvates and hydrates thereof. The rabeprazole pharmaceutical composition disclosed by the invention can inhibit the rabeprazole sodium from being damaged by gastric acid, and is small in side effect, rapid in treatment, relatively good in effect and high in patient compliance; the rabeprazole pharmaceutical composition has the advantages that the rabeprazole pharmaceutical composition is simple in preparation process and good in market prospect, and is an excellent medicine for treating peptic ulcer, and a pharmaceutical preparation can be delivered into the stomach by nasal feeding for some patients who cannot be administered by themselves, so that the effect of treating stomach diseases is achieved.

The invention discloses a defoaming agent adaptive to a digestive tract environment, and a preparation method and application thereof, and relates to the technical field of digestive tract examination assistance. The defoaming agent comprises simethicone, hyaluronidase, bromelain and sodium bicarbonate, and the preparation form is a capsule in which a quick-release drug-loading unit and an enteric drug-loading unit are mixed. The preparation method comprises the following steps: preparing the quick-release drug-loading unit, preparing the enteric drug-loading unit, and mixing and encapsulating. The defoaming agent is orally taken 25-35 minutes before gastroscopy, a closed loop of gastric acid neutralization, thick mucus degradation and foam removal effects can be formed, the problem of poor defoaming caused by mucus wrapping foam is solved, the field of view in the stomach is optimized, and the accuracy of stomach disease diagnosis is guaranteed.

This invention discloses a high-load XOR tumor-targeting therapy nanoplatform based on ROS activity and its applications, belonging to the field of nanobiomaterials. This high-load XOR tumor-targeting therapy nanoplatform, using a zeolite imidazole framework-8 (ZIF-8) as a carrier, contains xanthine oxidoreductase (XOR) with cellular enzymatic activity. It possesses the ability to target tumor cells and induce intracellular reactive oxygen species (ROS), leading to tumor cell death. Induction of intracellular ROS in tumor macrophages (TAMs) also supports the differentiation of macrophages into M1 types. ROS-induced apoptosis in tumor cells produces a series of tumor-associated antigens, which further promotes the infiltration and activation of macrophages in the tumor microenvironment. This, in turn, leads to increased infiltration of CD8+ T cells in the tumor, whose cytokine profile shows cytotoxic effects, indicating successful induction of an adaptive anti-tumor response. This novel nanomaterial offers a promising new strategy for the immunotherapy of gastric diseases.

The disclosure generally relates to soft gelatin oral dosage form. In particular the disclosure relates to an oral dosage form comprising a soft gelatin capsule and a liquid fill, where the liquid fill is a suspension of an H2 receptor antagonist in a hydrophobic / lipophilic excipient. The disclosure also relates to a method of treating a gastric disease or disorder by using said oral dosage form.

The invention relate to a liquid oral pharmaceutical dosage form, comprising a) pharmacologically effective amounts of at least one histamine H2- receptor antagonist in a hydrophobic / lipophilic liquid substantially free from water and b) pharmacologically effective amounts of at least one antacid, wherein a) and b) are physically separated from each other, a package comprising multiple liquid oral dosage forms as well as a method of treating a gastric disease or disorder by use of the liquid oral pharmaceutical dosage form.

The present invention discloses systems and methods for mapping gastric activity with an electrode array patch disposed over an abdomen skin surface of a patient. A method may include measuring electrical signals associated with gastric activity of the patient with the electrode array patch over a predetermined time period and concurrently receiving patient symptom information, determining one or more normalized biometrics from the measured electrical signals, correlating the one or more normalized biometrics and the patient symptom information, determining a measure of correlation, determining a measure of temporal association, and determining a gastrointestinal phenotype of the patient based at least in part on the measure of correlation and the measure of temporal association. The present invention advantageously enables mapping of gut motility patterns at high spatial resolution for the identification of gastric disorders and provides biomarkers of pathophysiology which include correlations with symptom severity profiles.

The invention belongs to the technical field of medicines, and particularly relates to application of hibiscus (the hibiscus is a plant hibiscus flower and an extract and an active monomer thereof) in preparation of medicines for treating stomach diseases (atrophic gastritis, gastric mucosal lesion and gastric cancer). The invention discloses application of hibiscus syriacus in treatment of gastric diseases. The application comprises at least one of chronic atrophic gastritis treatment, gastric mucosa protection and gastric cancer prevention. In-vitro experiments show that the shrub althea flower extract, shrub althea flower polyphenol, syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-beta-D-glucoside (IV) have obvious antioxidant activity and gastric mucosa protection activity, can obviously reduce the ROS content in ethanol-induced GES-1 cells and the expression of apoptosis marker protein Caspase-3 / Bax, and have a wide application prospect.

The application discloses a short-wave ultraviolet irradiation-based stomach disease treatment instrument, and belongs to the technical field of medical equipment.The application comprises a treatment instrument main body, a main pipe body, a probe end, an ultraviolet emission end and a treatment control module for controlling the treatment instrument main body; the modular design of the treatment instrument main body and the combination with the ultraviolet emission end improve the clinical operability and treatment effect, the combination with the rotary toothed disc driving mechanism enables the ultraviolet emission end to realize all-around twisting, covers the stomach area, the light-transmitting layer blocks infrared radiation while ensuring the ultraviolet transmittance, reduces the thermal stimulation on the stomach tissue, and enables medical staff to observe the irradiation effect in real time, realizes visual treatment, the treatment control module realizes the precision and intelligence of stomach disease treatment through a multi-unit cooperative architecture, generates a personalized scheme based on the disease type and the lesion position, monitors the physiological indexes of patients in real time and dynamically adjusts the treatment parameters, and improves the treatment safety and effectiveness.

The utility model relates to the technical field of medical supplies, in particular to a gastroscopy bag for stomach illness examination, which comprises a gastroscopy bag bottom, a dust cover, a liner, a waterproof film and a T-shaped partition plate, the dust cover is arranged at the top of the gastroscopy bag bottom, a built-in tray is arranged on one side of the T-shaped partition plate, and the waterproof film is arranged on the other side of the T-shaped partition plate. A liner made of medical-grade non-woven fabric is arranged at the inner bottom of the built-in tray; a T-shaped partition plate is fixed in the dustproof cover, a first inserting groove is formed in the bottom of the gastroscopy bag bottom, and a second inserting groove is formed in the inner side of the dustproof cover; the novel gastroscopy bag is provided with a structure for carrying out anti-collision and anti-abrasion protection on the gastroscope, damage to the gastroscope in the process of taking and placing the gastroscope is avoided, the function of preventing water or corrosive liquid from permeating into the gastroscopy bag from the bottom of the gastroscopy bag is achieved, and then the practicability can be effectively improved.

The application belongs to the field of organoid culture, and specifically discloses a culture method of monkey gastric organoids, and discloses a culture medium for culturing monkey gastric organoids, wherein the culture medium comprises (1) an expansion culture medium and (2) a complete culture medium; the application screens key regulation factors and appropriate concentrations for the growth of monkey gastric organoids according to the biological characteristics and growth characteristics of monkey gastric organs, optimizes the culture method, maintains the activity of monkey gastric organoids in vitro for a long time, and can be stably passaged, frozen, recovered, and cultured on a large scale for functional experiments, so as to provide a primate in-vitro model for the research on the mechanism of gastric diseases, toxicity testing, drug research and development, and the like.

A composition comprising: lactoperoxidase, an iodide salt, and a pharmaceutically acceptable carrier and / or excipient is provided, for use in the treatment or prevention of equine gastric ulcer syndro

The present invention belongs to the field of pharmaceutical technology, and relates to the treatment of gastric diseases, and in particular to a simethicone powder and its preparation method and application, comprising simethicone, alkaline compounds, fillers, dispersants and flavoring agents. The present invention is prepared into a powder that can be used in combination through creative prescriptions and processes, and is orally used to treat gastric diseases such as gastric acid and abdominal bloating, and can also be used as a defoaming agent before gastrointestinal endoscopy. After administration of different doses, the number of drug-effect hiccups in modeling mice was significantly reduced, and the volume of gastric accumulation was significantly reduced.

The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a Chinese medicine preparation for treating gastric disease, and a preparation method and application thereof. The Chinese medicine preparation comprises the following raw materials in parts by weight: 30-40 parts of white flower bitter lantern root, 25-35 parts of shrimp grass, 10-20 parts of dried orange peel, 12-18 parts of immature bitter orange, 6-10 parts of cucumber seeds, 8-10 parts of spiny jujube seeds, 2-5 parts of lily, and 1-3 parts of licorice. In the prescription, the white flower bitter lantern root promotes blood circulation and dredges the meridians, relieves swelling and relieves pain, and the shrimp grass dispels wind and clears heat, which are the main medicines; the dried orange peel regulates qi and strengthens the spleen, the immature bitter orange breaks qi and eliminates accumulation, and the cucumber seeds dispel wind and strengthen the stomach, promote digestion, which are the minister medicines; the spiny jujube seeds nourish the heart and calm the mind, and the lily nourishes yin and produces body fluid, which are the adjuvant medicines; and the licorice is used as the adjuvant to coordinate the various medicines. The whole prescription is reasonably compatible and treats atrophic gastritis together.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The invention belongs to the technical field of endoscopes, particularly relates to an intragastric double-endoscope collaborative visual diagnosis device, and aims to solve the problem that due to the fact that part of gastric diseases can be clearly diagnosed only by depending on long-time continuous observation, an existing gastroscope is difficult to meet the dynamic monitoring requirement. The capsule gastroscope comprises a capsule gastroscope body, a flexible gastroscope body and a magnetic attraction mechanism. The capsule gastroscope is internally provided with a liquid storage cavity used for containing adhesive liquid and has an auxiliary observation mode and a continuous observation mode. And the front end part of the flexible gastroscope is detachably connected to the capsule gastroscope. When the intragastric double-endoscope collaborative visual diagnosis device is used, after the flexible gastroscope conveys the capsule gastroscope to an observation position, the magnetic attraction mechanism applies magnetic attraction force to fix the capsule gastroscope to the stomach wall and trigger release of the adhesive liquid, the adhesive liquid adheres and fixes the capsule gastroscope to the stomach wall, the capsule gastroscope independently and continuously collects intragastric images, and the capsule gastroscope is used for detecting the intragastric images. And the capsule gastroscope falls off from the stomach wall until the bonding liquid loses efficacy due to the effect of gastric juice.

The present invention provides a vonoprazan fumarate composition and a preparation method thereof, belonging to the field of medical technology. Specifically, a vonoprazan fumarate composition is provided, comprising the following components: vonoprazan fumarate, vitamin C, an oil phase, and sodium bicarbonate or calcium carbonate; a preparation method of the vonoprazan fumarate composition is also provided. The vonoprazan fumarate composition provided by the present invention greatly improves the efficacy of treating gastric diseases, reduces the dosage of vonoprazan fumarate, and effectively solves the problem of large toxic and side effects of existing vonoprazan fumarate agents.

The invention provides a nucleic acid fragment of helicobacter pylori (HP) which is pathogenic to gastric cancer and application of the nucleic acid fragment of the helicobacter pylori (HP). In the invention, a novel gastric cancer treatment method is explored based on an HP pathogenic mechanism, a nucleic acid fragment (EC-HP-Fs) causing gastric cancer in HP is determined, and the nucleic acid fragment can participate in an HP-induced gastric cancer process through epigenetic regulation of expression of a host gene to promote the gastric cancer process, and can be used as a new target to treat gastric cancer. The invention also provides nucleic acid inhibitors for targeted modulation. The invention provides a new target for clinical treatment and detection of infectious stomach diseases caused by HP or HP.

The invention discloses a nutmeg stomach invigorating and consciousness restoring paste, and particularly relates to the technical field of health preserving products, the nutmeg stomach invigorating and consciousness restoring paste comprises the following components: active components: 20-40 g of fennel, 10-20 g of dried orange peel, 10-20 g of amomum cardamomum, 5-15 g of hawthorn, 3-8 g of safflower, 0.3-1 g of borneol, 0.02-0.1 g of artificial musk, 2-5 g of salvia miltiorrhiza, and 1-4 g of corydalis tuber, the weight ratio of borneol to azone serving as a transdermal enhancer is 2: 1 or 3: 1, the transdermal enhancer is 0.1-0.5 g of azone with the purity being greater than or equal to 99%, and the carrier is a breathable cloth bag with the pore diameter being 50-100 microns and the porosity being greater than or equal to 70%. Through deep combination of double-effect functions of invigorating the stomach and restoring consciousness, technical characteristics and multi-medical theories, the core advantages of the traditional natural therapy are reserved, the suitability and the effect are improved by means of the modern technology, a user can flexibly adopt part or all of the schemes according to own habits, and the application range is wide. The requirements of individualized selection, multidisciplinary fusion and non-drug home intervention are met, and an innovative solution is provided for chronic stomach disease conditioning and health management.

The present application provides a pharmaceutical preparation containing aspirin, a preparation method thereof, and an application thereof, wherein the pharmaceutical preparation contains aspirin enteric-coated microspheres and a second active ingredient, clopidogrel, wherein the aspirin enteric-coated microspheres are composed of a matrix and aspirin dispersed in the matrix; the matrix is ​​composed of hypromellose phthalate and ethylcellulose; and aspirin accounts for 50-70% of the weight of the enteric-coated microspheres. The pharmaceutical preparation of the present application satisfies the requirements of both easy swallowing and low gastric dissolution, and provides good compliance for patients with dysphagia and / or gastric disease.

The invention discloses a sea cucumber intestine polypeptide and application thereof in preparation of a medicine for treating gastric diseases, and relates to the technical field of biological medicines. The amino acid sequence of the sea cucumber intestine polypeptide comprises one or more of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3. Compound papain and neutral protease are selected for hydrolyzing sea cucumber intestines, the hydrolysis degree serves as the evaluation standard, the optimal hydrolysis condition of the sea cucumber intestines is determined through single-factor and response surface tests, and three sea cucumber intestine polypeptides with the best in-vitro antioxidant activity are screened out from sea cucumber intestine polypeptides prepared through enzymolysis. The screened sea cucumber intestine polypeptide has a good application prospect in treatment and prevention of gastric diseases caused by gastric mucosa damage.